Hormone therapy with or without chemo for early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have had surgery for breast cancer.
- Your cancer is hormone receptor-positive (ER-positive) and HER2-negative, with an Oncotype DX Recurrence Score of 25 or lower.
- You have not had chemotherapy for this cancer before, and you have not taken a CDK4/6 inhibitor before.
- You have no other serious health conditions that could make treatment risky.
- You are postmenopausal or a man.
- Your surgery for breast cancer happened less than 16 weeks before joining the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This study tests whether some people with a certain type of breast cancer (ER-positive, HER2-negative) can safely skip chemotherapy. After surgery, they receive a targeted pill (ribociclib) plus hormone therapy instead. The goal is to see if this approach works just as well with fewer side effects.
This trial studies whether adding ribociclib to standard hormone (endocrine) therapy lowers the risk of breast cancer coming back in early-stage, hormone-receptor–positive cancer. It mainly looks at safety and how well the treatment controls cancer after surgery and (sometimes) prior hormone treatment.
This trial tests a new approach: starting with a targeted pill (ribociclib) plus hormone therapy (an aromatase inhibitor), instead of immediate chemotherapy, for women with a specific type of breast cancer (ER low-positive, HER2-negative) that is growing quickly. If eligible, you would not have received any prior treatment for your advanced cancer.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Hear when a new Anatomic Stage II Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.